On a relative basis, the stock has outperformed the S&P 500 by 10.83% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.09% in the last 1 week, and is up 12.62% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -81.24% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $28.08 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $4.42 and the 200 Day Moving Average price is recorded at $6.30.
The stock has recorded a 20-day Moving Average of 6.11% and the 50-Day Moving Average is 10.04%.
Celldex Therapeutics (NASDAQ:CLDX): On Fridays trading session , Opening price of the stock was $4.66 with an intraday high of $4.73. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.59. However, the stock managed to close at $4.64, a loss of 0.22% for the day. On the previous day, the stock had closed at $4.65. The total traded volume of the day was 1,490,201 shares.
In an insider trading activity, Catlin Avery W, officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., unloaded 25,000 shares at an average price of $18 on November 23, 2015. The total amount of the transaction was worth $450,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.